Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


“Bio-buck” Deals A Good Risk-Sharing Strategy, Pharma Execs Say At BIO

Executive Summary

Bio-buck deals, those back-end-loaded, early-stage collaborations that grab headlines because of the big dollars promised, are a win-win risk share, big pharma execs say

You may also be interested in...

Daiichi Gets Into Generics With Stake In Ranbaxy

Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the In Vivo blog. Visit the blog at

Bristol Recharges Kai Heart Attack Candidate

Just because a marriage ends with a breakup doesn't mean a happy union with someone else isn't in the stars - especially when it comes to partnerships between big pharma and biotech

Merck Hopes To Make A Success Story of CETP Inhibitors And Obesity Drugs

Merck is hoping to find success where other firms have failed: its late stage pipeline includes two programs in drug classes where the lead candidates from other companies have not managed to gain approval

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts